Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Five patients with systemic lupus erythematosus (SLE) developed septic arthritis. Neisseria gonorrheae, Staphyloccocus aureus, Proteus and Escherichia coli were the offending bacterial organisms. Predisposing factors included systemic and local corticosteroids, aseptic necrosis of bone and synovitis due to SLE. The diagnosis was made by culture of the organisms from the synovial fluid. Three patients recovered without residual joint damage, one required corrective arthroplasty and one died from overwhelming infection.
 ...
PMID:Septic arthritis in systemic lupus erythematosus. 118 38

ELISA quantitation of antibodies to Klebsiella pneumonia, Proteus mirabilis, and Yersinia enterocolitica was conducted in 75 ankylosing spondylitis (AS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) probands and in 262 of their first-degree relatives. The control group comprised 28 healthy donors. Sixteen (64 per cent) AS probands (12 with B27+) and 26 (30.2 per cent) their relatives (14 with B27+) were found to have high titres of antibodies to Klebsiella pneumonia. In 18 (60 per cent) active RA probands and 27 (23.7 per cent) relatives, antibodies to Proteus mirabilis were found. The obtained results suggest the presence of genetic determinants of the increased immune response to various infectious agents, at least in the AS cases. The possibility of Enterobacteriaceae acting as polyclonal stimulators is not excluded.
 ...
PMID:[Circulation of intestinal infection in the families of patients with rheumatic diseases and the state of humoral immunity to enterobacterial antigens]. 277 62

Increased levels of Proteus antibodies were found in patients with rheumatoid arthritis and coeliac disease, when compared to normal controls or patients with SLE and sarcoidosis.
 ...
PMID:Antibodies to Proteus in rheumatoid arthritis. 304 79

Between 1983 and 1986, 40 hip arthroplasties in 40 patients with documented deep infection were reimplanted using Palacos Gentamicin at The Hospital for Special Surgery. Palacos Gentamicin was added to the standard protocol, which included removal of the prosthesis, cement, if present, and a thorough debridement of infected and necrotic tissue, six weeks of intravenous antibiotics with a postpeak serum bactericidal titer of at least 1:8 against the infecting bacteria, followed by reimplantation of the hip. Sixteen of the patients also had the placement of gentamicin-impregnated beads at the time of prosthetic removal. All patients had a deep periprosthetic infection, 13 with Staphylococcus epidermidis, seven Staphylococcus aureus, four Streptococcus, three Enterococcus, three with gram-positive bacteria, four Escherichia coli, two Proteus, one Pseudomonas, and three anaerobic organisms. At an average follow-up period of five years (range, two to ten), two of the 40 hips (5%) developed recurrent infection. These cases recurred at one month in a patient immunocompromised by end-stage systemic lupus erythematosus (S. epidermidis) and at five months in a patient with severe titanium metallosis (S. aureus). No recurrence was noted in eight cases with gram-negative organisms or in three cases of mixed infections. No infection recurred after five months in the remaining patients before their death or last follow-up examination. Of the remaining 38 hips, 16 died of causes unrelated to the hip, leaving 21 with an average follow-up period of 7.5 years. Clinical results in these patients were 14 excellent, five good, two fair, and no poor results.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Palacos gentamicin for the treatment of deep periprosthetic hip infections. 811 2

Renal artery aneurysm is extremely rare among patients with systemic lupus erythematosus.(SLE). Herein, we report on a 22-year-old male lupus patient who presented with acute abdominal pain, anemia and subsequent hypertension. Abdominal computed tomography revealed a peri-renal hematoma over the right kidney. A renal angiography revealed bilateral renal microaneurysms. The patient subsequently developed a right-side retroperitoneal abscess 4 weeks after hematoma formation and received an emergent laparotomy with drainage. Subsequent culture ofthe abscess-derived fluid revealed the presence of Proteus mirabilis and Escherichia coli. Following appropriate antipyretic and immunosuppressive drugs therapy, the patient recovered successfully. To the best of our knowledge, this is the first report of SLE associated with a retro-peritoneal abscess probably secondary to a ruptured renal microaneurysm.
Lupus 2003
PMID:Ruptured renal microaneurysms complicated with a retroperitoneal abscess for a patient with systemic lupus erythematosus. 1272 57

It has been suggested that Proteus infection may be involved in the pathogenesis of rheumatoid arthritis (RA). Bacterial and peptide immune responses in patients with RA and other control subjects were investigated in two geographically different populations. Serum samples from Finnish patients with early ( n=72) and advanced ( n=27) RA and 30 Finnish healthy controls, as well as from Japanese RA patients from two different locations: Tokyo ( n=30) and Otsu ( n=30), 18 patients with systemic lupus erythematosus (SLE) and 23 Japanese healthy controls were all screened for the total, and class-specific (IgG, IgA and IgM) antibodies against Proteus mirabilis, Escherichia coli and Serratia marcescens by indirect immunofluorescence assay. These samples were also tested for the determination of levels of isotypic antibodies against the shared epitope involving 16-mer synthetic peptides containing the EQRRAA or ESSRAL sequences and compared to scrambled control peptide by using an enzyme-labeled immunosorbent assay method. Significantly elevated levels of IgG and IgM antibodies to P. mirabilis and antibodies against both EQRRAA and ESSRAL peptides were detected in sera of Finnish patients with early and advanced RA, and in Japanese patients from Otsu or Tokyo compared to their corresponding control groups. In contrast, no difference either in the total or in any of the isotypic antibodies were observed between these groups when serum samples were screened against each of E. coli and S. marcescens or against the control peptide. Furthermore, there was a significant correlation between the antibody levels against Proteus bacteria only and both EQRRAA and ESRRAL peptides. Our findings support the possibility for specific involvement of P. mirabilis in the etiopathogenesis of RA even in early cases.
 ...
PMID:Antibacterial and antipeptide antibodies in Japanese and Finnish patients with rheumatoid arthritis. 1504 28

There have been attempts to reveal the possible associations between systemic lupus erythematosus (SLE) and gut microbiota. Using MRL/lpr mice, this study was performed to reveal whether early and short-term interventions in gut microbiota affect lupus. MRL/lpr mice were treated with antibiotics or fecal microbiota transplantation (FMT) before onset. Then, prednisone was used to treat the lupus mice with initially different gut microbiota compositions. The compositions of gut microbiota were assessed by the V3-V4 region of 16S rRNA gene sequence. Early and short-term antibiotics exposure aggravated lupus severity by depleting beneficial gut microbiota for lupus, such as Lactobacillus and Bifidobacterium, and enriching harmful gut microbiota for lupus, such as Klebsiella and Proteus. FMT alleviated lupus severity by renovating the antibiotic-induced dysbiosis of gut microbiota in the following 1 week after antibiotics exposure. Besides, short-term antibiotics exposure before onset imposed no significant effects on lupus progression, but the following one week of FMT suppressed lupus progression. Moreover, the short-term antibiotics or FMT before onset inhibited the therapeutic efficiency of prednisone on lupus from 9 to 13 weeks old of MRL/lpr mice. These data demonstrate that the gut microbiota before onset is important for lupus severity, progression and treatment.
 ...
PMID:Early and Short-Term Interventions in the Gut Microbiota Affects Lupus Severity, Progression, and Treatment in MRL/lpr Mice. 3234 76